Mark Mossler's most recent trade in C4 Therapeutics Inc was a trade of 56,980 Common Stock done . Disclosure was reported to the exchange on Feb. 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | Mark Mossler | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2026 | 56,980 | 75,184 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Mark Mossler | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 9,420 | 75,184 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Mark Mossler | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.89 per share. | 13 Feb 2026 | 3,268 | 71,916 | - | 1.9 | 6,177 | Common Stock |
| C4 Therapeutics Inc | Mark Mossler | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 14 Feb 2025 | 1,586 | 18,204 | - | 3.2 | 5,043 | Common Stock |
| C4 Therapeutics Inc | Mark Mossler | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 27,430 | 27,430 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Mark Mossler | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 18,290 | 19,790 | - | 0 | Common Stock |